Replies to post #237104 on Biotech Values

[whatisthecolorofmone]

DD Please try this link

https://investorplace.com/2021/02/artl-stock-alert-the-big-reason-biopharma-artelo-biosciences-is-rocketing-today/

[DewDiligence]

DBTX +21% on interim phase-1b data re hearing-loss phophylactic for patients taking cisplatin:

https://www.globenewswire.com/news-release/2022/06/28/2470202/0/en/Decibel-Therapeutics-Reports-Positive-Data-from-Interim-Analysis-of-Ongoing-Phase-1b-Clinical-Trial-of-DB-020-in-Patients-Receiving-Cisplatin-Chemotherapy.html

In this trial, each patient received DB-202 in one ear and placebo in the other, providing a control in a single-arm design.

Even after today’s bounce, the stock is down 85% from its 2021 IPO (#msg-161773246).

[crudeoil24]

DBTX > Decibel Therapeutics Shares Continue to Rally After Good Study Data >DBTX
12:58 pm ET June 29, 2022 (Dow Jones) Print

By Colin Kellaher


Shares of Decibel Therapeutics Inc. surged more than 30% on Wednesday, extending Tuesday's gains after the clinical-stage biotechnology company reported positive study results.

The Boston company on Tuesday said interim data from a Phase 1b study of DB-020 support continued development of the drug in the protection against ototoxicity, or hearing loss, in cancer patients receiving cisplatin chemotherapy.

Decibel said 87% of patients who experienced ototoxicity in their placebo-treated ear were protected from the side effect in their ear treated with DB-020.

In a research note, Citi analyst Neena Bitritto-Garg, who has a "buy" rating and a $15 target price on Decibel shares, said the study data mark "a clear win" the company.

The analyst also noted that Decibel remains focused on its earlier-stage gene-therapy portfolio, with an ultimate goal of licensing DB-020 to a company with an oncology sales force.

Decibel shares, which rose 18.3% on Tuesday, were recently changing hands at $3.52, up 32.9%.


Write to Colin Kellaher at [e-mail]


(END) Dow Jones Newswires

[DewDiligence]

REGN acquires DBTX for $4.00/sh cash +CVR; the cash portion of the deal is a 43% premium to yesterday’s close, but a 78% discount to DBTX’s 2021 IPO (#msg-161773246):

https://finance.yahoo.com/news/regeneron-acquire-decibel-therapeutics-strengthening-113000878.html

Regeneron Pharmaceuticals and Decibel Therapeutics…today announced a definitive agreement for the acquisition of Decibel by Regeneron at a price of $4.00 per share of Decibel common stock payable in cash at closing, with an additional non-tradeable contingent value right (CVR) to receive up to $3.50 per share in cash upon achievement of certain clinical development and regulatory milestones for Decibel’s lead investigational candidate, DB-OTO, within specified time periods.

The nominal deal value (excluding the CVR) is $109M.